RT Journal Article
SR Electronic
T1 Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.28.24309678
DO 10.1101/2024.06.28.24309678
A1 Seo, Aaron
A1 Xiao, Weihong
A1 Gjyshi, Olsi
A1 Yoshida-Court, Kyoko
A1 Wei, Peng
A1 Swanson, David
A1 Napravnik, Tatiana Cisneros
A1 Grippin, Adam
A1 Venkatesan, Aradhana M
A1 Jacobsen, Megan C
A1 Fuentes, David T
A1 Lynn, Erica
A1 Sammouri, Julie
A1 Jhingran, Anuja
A1 Joyner, Melissa
A1 Lin, Lilie L
A1 Colbert, Lauren E
A1 Gillison, Maura L
A1 Klopp, Ann H
YR 2024
UL http://medrxiv.org/content/early/2024/06/30/2024.06.28.24309678.abstract
AB Purpose The human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response.Experimental Design Sixty-six patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care (SOC) treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma samples were collected at baseline, during weeks 1, 3, and 5 of chemoRT, and 3-4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy.Results The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared to SOC. HPV cfDNA clearance correlated with better 2-yr RFS (92.9% vs. 30%, log-rank p=0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index (CI) 0.83, which improved when combined with MRI response (CI 0.88).Conclusions HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at first follow-up predict RFS, and the therapeutic HPV vaccine was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the University of Texas MD Anderson Cancer Center Human Papillomavirus Moonshot Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the University of Texas MD Anderson Cancer center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe de-identified data that support the findings of this study will be available on reasonable request. The data are not publicly available due to protected health information that could compromise the privacy of research participants.